Jason Najum's Blog

Cybin: Top Value Psychedelic Stock (NYSE:CYBN)

The psychedelic medicine sector provides some unique value investment opportunities. Here’s why Cybin could be the best value bet among this group of biotech pioneers.

FDA's MDMA Decision A Setback, Long-Term Outlook For Psychedelic Stocks Unchanged

The FDA has rejected MDMA therapy, but this setback could potentially benefit other psychedelic stocks.

MindMed And Other Psychedelic Stocks Brace For FDA's Decision On MDMA Therapy (MNMD)

A look at the FDA's upcoming decision on MDMA therapy and how it might affect other psychedelic stocks.

The Top Psychedelic Stories of 2023

As we close out the year, let’s take a look back at some of the more important milestones in the psychedelic medicine space. From legalization to clinical trials, the psychedelic sector continued to make steady progress on all fronts.

Business Insider: Psychedelic Stocks With Buy Ratings

The psychedelic medicine industry continues to get attention and gain credibility in the investment world.

Stories of Healing: My First Ketamine Therapy Experience

Microdose's editor Jason Najum shares his personal experience with ketamine psychedelic therapy.

A Deeper Look at atai Life Sciences' Company Update

Microdose digs in and gives you a deeper look at Atai's programs and developmental portfolio

Benzinga: Psychedelic Companies With Solid Fundamentals Will Survive

Psychedelic startups face a more challenging time raising capital amid market volatility.

Raising Capital in Today’s Psychedelic Medicine Market

The ability to raise capital is one of the most important factors in the success of any company, and is downright essential for biotech startups faced with the lean years of long R&D horizons.

MindMed Uplists to the Nasdaq: A First Look

MindMed announced that the Nasdaq listing is official and will begin trading next week. MindMed shareholders and the psychedelic industry as a whole have been waiting for this moment.